FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:325 August 3, 1995 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Selhub, J. PubMed Citation

To the Editor: The article "Association between Plasma Homocysteine Concentrations and Extracranial Carotid-Artery Stenosis"¹ and the accompanying editorial "Can Lowering Homocysteine Levels Reduce Cardiovascular Risk?"² (Feb. 2 issue) draw attention to the increased risk of vascular disease in the presence of increased plasma concentrations of what both the article and the editorial term "homocysteine."

The words "homocysteine" and "homocystine" were coined by du Vigneaud and coworkers, who discovered these compounds some 60 years ago, to designate, respectively, the reduced (sulfhydryl) and the oxidized (disulfide) forms of these next-higher homologues of cysteine and cystine.³ Normal human plasma contains a total concentration . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Toole, J. F., Malinow, M. R., Chambless, L. E., Spence, J. D., Pettigrew, L. C., Howard, V. J., Sides, E. G., Wang, C.-H., Stampfer, M. (2004). Lowering Homocysteine in Patients With Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA 291: 565-575 [Abstract] [Full Text]  
• RAGONE, R. (2002). Homocystine solubility and vascular disease. FASEB J. 16: 401-404 [Abstract] [Full Text]  
• Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., Klibanski, A. (2001). Effects of Growth Hormone (GH) Administration on Homocyst(e)ine Levels in Men with GH Deficiency: A Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 86: 1518-1524 [Abstract] [Full Text]  
• Bova, I., Chapman, J., Sylantiev, C., Korczyn, A. D., Bornstein, N. M. (1999). The A677V Methylenetetrahydrofolate Reductase Gene Polymorphism and Carotid Atherosclerosis. Stroke 30: 2180-2182 [Abstract] [Full Text]  
• Jacobsen, D. W. (1998). Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 44: 1833-1843 [Abstract] [Full Text]  
• Lentz, S. R., Malinow, M. R., Piegors, D. J., Bhopatkar-Teredesai, M., Faraci, F. M., Heistad, D. D. (1997). Consequences of Hyperhomocyst(e)inemia on Vascular Function in Atherosclerotic Monkeys. Arterioscler. Thromb. Vasc. Bio. 17: 2930-2934 [Abstract] [Full Text]  
• Evans, R. W., Shaten, B. J., Hempel, J. D., Cutler, J. A., Kuller, L. H. (1997). Homocyst(e)ine and Risk of Cardiovascular Disease in the Multiple Risk Factor Intervention Trial. Arterioscler. Thromb. Vasc. Bio. 17: 1947-1953 [Abstract] [Full Text]